Medication-Related Osteonecrosis of the Jaws: Current Views on Active Drug Groups, Diagnosis and Treatment

Abstract

ABSTRACT Medication-related osteonecrosis of the jaws (MRONJ) is a drug-related pathology characterized by the progressive destruction of jaw bones arising from the disruptive effects of antiresorptive and antiangiogenic drugs on bone turnover and vascularization. Although most MRONJ cases develop due to the use of intravenous bisphosphonates and subcutaneous denosumab, novel pharmacological agents such as vascular endothelial growth factor and tyrosine kinase inhibitors, which have been increasingly used especially in the field of oncology, have been reported to have similar side effects. Accordingly, drug groups at risk of causing MRONJ are constantly updated. MRONJ has numerous clinical and radiographic findings depending on the severity and stage of the pathology and the appropriate treatment protocol is determined according to the patient's symptoms, severity of the findings, and stage of MRONJ. The primary goal of MRONJ treatment is to control bone necrosis, pain, and infection, while conservative methods such as oral hygiene motivation are employed in early-stage MRONJ cases, invasive surgical procedures become necessary in advanced stages. Nonetheless, it is imperative for dental practitioners to have up-to-date and sufficient knowledge about clinical and radiographic findings for the differential diagnosis and treatment planning of MRONJ. The aim of this review is to evaluate the current drug groups, clinical and radiographic findings, differential diagnosis and treatment protocols of MRONJ in the light of recent literature.

Keywords

• Medication-related osteonecrosis of the jaw
• antiresorptive
• antiangiogenic
• diagnostic imaging
• treatment protocols

İlaçlara Bağlı Çene Kemiği Osteonekrozu: Etken İlaç Grupları, Tanı ve Tedaviye Dair Görüşler ve Kavramlar

Öz

ÖZ İlaçlara bağlı çene kemiği osteonekrozu (MRONJ) antirezorptif ve antianjiyojenik ilaçların kemik döngüsü ve vaskülarizasyonu üzerindeki etkilerine bağlı olarak çene kemiklerinde ortaya çıkan, kemik dokusunun ilerleyici yıkımıyla karakterize bir patolojidir. MRONJ olgularının büyük bir kısmı IV bisfosfonat ve subkutan denosumab kullanımına bağlı gelişmektedir. Ancak son yıllarda özellikle onkoloji alanında kullanılmaya başlanan vasküler epiteliyal büyüme faktörü ve tirozin kinaz inhibitörleri gibi bazı farmakolojik ajanların da benzer yan etkilere sahip olduğu rapor edilmekte ve dolayısı ile MRONJ gelişimine yol açma riski taşıyan ilaç grupları devamlı güncellenmektedir. MRONJ’un klinik ve radyografik olarak tanımlanmış pek çok bulgusu mevcut olup bu bulgular hastalığın şiddetine ve evresine göre olgudan olguya değişkenlik göstermekte ve uygun tedavi protokolüne hastanın bulgularına, bulguların şiddetine ve hastalığın evresine göre karar verilmektedir. MRONJ tedavisinde temel amaç kemik nekrozunun, ağrı ve enfeksiyonun kontrol altına alınmasıdır. Bu amaçla, erken evre MRONJ olgularında ağız hijyen motivasyonu gibi konservatif yöntemlere başvurulurken ileri evrelerde ise invaziv cerrahi işlemler zorunlu hale gelmektedir. Diş hekimlerinin MRONJ’un klinik ve radyografik bulguları konusunda güncel ve yeterli bilgiye sahip olması MRONJ’un klinik ve radyografik ayırıcı tanısında ve tedavi planlamasında önemli rol oynamaktadır. Bu derlemenin amacı, MRONJ gelişimine neden olan ilaç gruplarının, MRONJ’un klinik ve radyografik bulgularının, ayırıcı tanısının ve farklı tedavi yaklaşımlarının güncel literatür rehberliğinde irdelenmesidir.

Anahtar Kelimeler

• İlaçlara bağlı çene kemiği osteonekrozu
• antirezorptif
• antianjiyojenik
• tanısal görüntüleme
• tedavi protokolleri

Kaynakça

1. 1. Di Fede O, Canepa F, Panzarella V, Mauceri R, Del Gaizo C, Bedogni A, Fusco V, Tozzo P, Pizzo G, Campisi G, Galvano A. The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols. Int J Environ Res Public Health 2021; 18:8432.
2. 2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-7.
3. 3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67:2-12.
4. 4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014; 72:1938-56.
5. 5. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125-32.
6. 6. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30:3-23.
7. 7. Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal; 25:e71-e83.
8. 8. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 2022; 80:920-43.

9. 9. Gaêta-Araujo H, Vanderhaeghen O, Vasconcelos KF, Coucke W, Coropciuc R, Politis C, Jacobs R. Osteomyelitis, osteoradionecrosis, or medication-related osteonecrosis of the jaws? Can CBCT enhance radiographic diagnosis? Oral Dis 2021; 27:312-9.
10. 10. He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci 2020; 12:30.
11. 11. Klingelhöffer C, Klingelhöffer M, Müller S, Ettl T, Wahlmann U. Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw? Dentomaxillofac Radiol 2016; 45:20160065.
12. 12. Maruotti N, Corrado A, Neve A, Cantatore FP. Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol 2012; 68:1013-8.
13. 13. AlDhalaan NA, BaQais A, Al-Omar A. Medication-related Osteonecrosis of the Jaw: A Review. Cureus 2020; 12:e6944.
14. 14. Hampson G, Fogelman I. Clinical role of bisphosphonate therapy. Int J Womens Health 2012; 4:455-69.
15. 15. Srivastava T, Alon US. The role of bisphosphonates in diseases of childhood. Eur J Pediatr 2003; 162:735-51.
16. 16. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38:617-27.
17. 17. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993; 3:13-6.
18. 18. Tanrikol B, Mağat G. Bifosfonatlar ve Çenelerde Görülen Osteonekroz. SABD 2022; 12:345–51.
19. 19. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH. Bishosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007; 1117:209-57.
20. 20. Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther 2022; 39:58-74.
21. 21. Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127:117-35.
22. 22. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48:3082-92.
23. 23. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24:153-61.
24. 24. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016; 375:1532-43.
25. 25. Tabouret T, Gregory T, Dhooge M, Brezault C, Mir O, Dréanic J, Chaussade S, Coriat R. Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis. Invest New Drugs 2015; 33:1144-7.
26. 26. Aldridge SE, Lennard TW, Williams JR, Birch MA. Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun 2005; 335:793-8.
27. 27. Mawardi H, Enzinger P, McCleary N, Manon R, Villa A, Treister N, Woo SB. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol 2016; 7:E81-7.
28. 28. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122:181-8.
29. 29. Erovigni F, Gambino A, Cabras M, Fasciolo A, Bianchi SD, Bellini E, Fusco V. Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. Dent J (Basel) 2016; 4:39.
30. 30. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315:971-9.
31. 31. Carmi C, Mor M, Petronini PG, Alfieri RR. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol 2012; 84:1388-99.
32. 32. Mauceri R, Panzarella V, Morreale I, Campisi G. Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int J Oral Maxillofac Surg 2019; 48:1530-2.
33. 33. van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Debruyne PR, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 2018; 26:869-78.
34. 34. Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, Lesko LJ, Gong Y. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). J Bone Miner Res 2016; 31:336-40.
35. 35. Lu W, Guo Q, Ma Z, Liu L, Zhao Z. Lenvatinib and osteonecrosis of the jaw: A pharmacovigilance study. Eur J Cancer 2021; 150:211-3.
36. 36. Kezic A, Popovic L, Lalic K. mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand? Oxid Med Cell Longev 2018; 2018:2640342.
37. 37. Konings IR, Verweij J, Wiemer EA, Sleijfer S. The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets 2009; 9:439-50.
38. 38. Akkach S, Shukla L, Morgan D. Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report. Br J Oral Maxillofac Surg 2019; 57:688-90.
39. 39. Af N, Nifosì, Nifosì. Osteonecrosis of the jaw in a patient treated with denosumab and temsirolimus. SAJ Case Rep 2017; 4:1–4.
40. 40. Santos-Silva AR, Belizário Rosa GA, Castro Júnior Gd, Dias RB, Prado Ribeiro AC, Brandão TB. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115:e32-6.
41. 41. King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127:289-99.
42. 42. Pavese F, Rotondaro S. Use of Radium223 in metastatic prostate cancer patient in treatment with denosumab: a potential trigger for Osteonecrosis of the jaw? A case report. Qeios 2021.
43. 43. Topaloglu G, Koseoglu OT, Karaca C, Kosemehmetoglu K. The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw. J Craniomaxillofac Surg 2017; 45:1158-64.
44. 44. Bindakhil M, Shanti RM, Mupparapu M. Raloxifene-induced osteonecrosis of the jaw (MRONJ) with no exposure to bisphosphonates: clinical and radiographic findings. Quintessence Int 2021; 52:258-63.
45. 45. Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. Front Immunol 2018; 9:444.
46. 46. Teoh L, Moses G, Nguyen AP, McCullough MJ. Medication-related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications. Br J Clin Pharmacol 2021; 87:2767-76.
47. 47. Favia G, Tempesta A, Limongelli L, Crincoli V, Piattelli A, Maiorano E. Metastatic Breast Cancer in Medication-Related Osteonecrosis Around Mandibular Implants. Am J Case Rep 2015; 16:621-6.
48. 48. Keribin P, Guerrot D, Jardin F, Moizan H. Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report. J Oral Maxillofac Surg 2017; 75:2599-605.
49. 49. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clin Ther 2017; 39:2216-29.
50. 50. Suryani IR, Ahmadzai I, Shujaat S, Ma H, Jacobs R. Non-antiresorptive drugs associated with the development of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. Clin Oral Investig 2022; 26:2269-79.
51. 51. Wong L-S, Tay K-K, Chieng Y-L. Osteonecrosis of mandible: A rare complication of long-term steroid use. J Oral Maxillofac Surg Med Pathol 2015; 27:255–7.
52. 52. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine 2012; 41:183-90.
53. 53. Henien M, Carey B, Hullah E, Sproat C, Patel V. Methotrexate-associated osteonecrosis of the jaw: A report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol 2017; 124:e283-7.
54. 54. Milosavljević M, Jovanović M, Folić M, Živić M, Zdravković D, Veličković S, Janković S. Possible association of methotrexate use with osteonecrosis of the jaw: Systematic review. J Stomatol Oral Maxillofac Surg 2022; 123:e458-63.
55. 55. Aghaloo TL, Tetradis S. Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases. J Oral Maxillofac Surg 2017; 75:129-42.
56. 56. Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent 2021; 7:47.
57. 57. Wongratwanich P, Shimabukuro K, Konishi M, Nagasaki T, Ohtsuka M, Suei Y, Nakamoto T, Verdonschot RG, Kanesaki T, Sutthiprapaporn P, Kakimoto N. Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review. Dentomaxillofac Radiol 2021; 50:20200417.
58. 58. Leite AF, Ogata Fdos S, de Melo NS, Figueiredo PT. Imaging findings of bisphosphonate-related osteonecrosis of the jaws: a critical review of the quantitative studies. Int J Dent 2014; 2014:784348.
59. 59. Baba A, Goto TK, Ojiri H, Takagiwa M, Hiraga C, Okamura M, Hasegawa S, Okuyama Y, Ogino N, Yamauchi H, Kobashi Y, Yamazoe S, Munetomo Y, Mogami T, Nomura T. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. Dentomaxillofac Radiol 2018; 47:20170323.
60. 60. Tsuchimochi M, Kurabayashi T. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication). Jpn Dent Sci Rev 2019; 55:1-4.
61. 61. Kim JW, Kwak MK, Han JJ, Lee ST, Kim HY, Kim SH, Jung J, Lee JK, Lee YK, Kwon YD, Kim DY. Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2021; 28:279-96.
62. 62. Cardoso CL, Barros CA, Curra C, Fernandes LM, Franzolin SO, Júnior JS, De Antoni CC, Curi MM. Radiographic Findings in Patients with Medication-Related Osteonecrosis of the Jaw. Int J Dent 2017; 2017:3190301.
63. 63. Suei Y, Taguchi A, Tanimoto K. Diagnostic points and possible origin of osteomyelitis in synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome: a radiographic study of 77 mandibular osteomyelitis cases. Rheumatology 2003; 42:1398-403.
64. 64. Shimamoto H, Grogan TR, Tsujimoto T, Kakimoto N, Murakami S, Elashoff D, Aghaloo TL, Tetradis S. Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws? Dentomaxillofac Radiol 2018; 47:20170290.
65. 65. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 2010; 14:311-7.
66. 66. Guggenberger R, Koral E, Zemann W, Jacobsen C, Andreisek G, Metzler P. Cone beam computed tomography for diagnosis of bisphosphonate-related osteonecrosis of the jaw: evaluation of quantitative and qualitative image parameters. Skeletal Radiol 2014; 43:1669-78.
67. 67. Ariji Y, Izumi M, Gotoh M, Naitoh M, Katoh M, Kuroiwa Y, Obayashi N, Kurita K, Shimozato K, Ariji E. MRI features of mandibular osteomyelitis: practical criteria based on an association with conventional radiography features and clinical classification. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105:503-11.
68. 68. De Antoni CC, Matsumoto MA, Silva AAD, Curi MM, Santiago Júnior JF, Sassi LM, Cardoso CL. Medication-related osteonecrosis of the jaw, osteoradionecrosis, and osteomyelitis: A comparative histopathological study. Braz Oral Res 2018; 32:e23.
69. 69. Obinata K, Shirai S, Ito H, Nakamura M, Carrozzo M, Macleod I, Carr A, Yamazaki Y, Tei K. Image findings of bisphosphonate related osteonecrosis of jaws comparing with osteoradionecrosis. Dentomaxillofac Radiol 2017; 46:20160281.
70. 70. Ogura I, Sasaki Y, Kameta A, Sue M, Oda T. Characteristic Multimodal Imaging of Medication-Related Osteonecrosis of the Jaw: Comparison Between Oral and Parenteral Routes of Medication Administration. Pol J Radiol 2017; 82:551-60.
71. 71. Atiea T, Henien M, Sproat C, Thavaraj S, Patel V. Cemento-Osseous dysplasia-related jaw necrosis − a case report and literature review. Dent Update 2019; 46:62-7.
72. 72. Özarslan SK, Yılmaz HH, Aksoy MÇ, Baykul T. Florid cemento-osseous dysplasia: a case report. Ata Diş Hek Fak Derg 2011; 2011:128-32.
73. 73. Seehra J, Sloan P, Oliver RJ. Paget’s Disease of Bone and Osteonecrosis. Dent Update 2009; 36:166-8.
74. 74. Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, Herlofson BB, Ristow O, Kofod T. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges. Oral Dis 2019; 25:1815-21.